As of Nov 19, 2026, 0 of 1 active firms rate ARTL a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ARTL EPS & revenue forecast
EPS · THIS QUARTER
$-1.57
Range $-1.57 – $-1.57 · 1 analysts · -78% YoY
Next period, 1 analysts expect Artelo Biosciences Inc to earn $-1.57 a share (range $-1.57 – $-1.57), versus $-7.02 a year earlier. , growing to $-5.28 the year after.
REVENUE · THIS QUARTER
—
Range — – — · 1 analysts
Revenue is expected to reach — (range — – —). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Artelo Biosciences Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ARTL.
#1
Jason Kolbert
D. Boral Capital · Rank #562
Neutral
No targeton ARTL
Overall win rate
22%
+ Follow
#2
Jason McCarthy
Maxim Group · Rank #567
Neutral
No targeton ARTL
Overall win rate
30%
+ Follow
#3
Vernon Bernardino
HC Wainwright & Co. · Rank #582
Buy
$5.00+231.1% to target
Overall win rate
14%
+ Follow
ARTL stock forecast FAQ
Is ARTL stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 1 active firms as of Nov 19, 2026, 0 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover ARTL?+
1 active firms have a recognized rating on Artelo Biosciences Inc as of Nov 19, 2026.
Who is the most accurate analyst covering ARTL?+
Among analysts who currently cover ARTL, Jason Kolbert of D. Boral Capital has the strongest overall Quantellect track record (Rank #562). Their current call is Neutral.
What is Artelo Biosciences Inc's projected EPS for next quarter?+
The consensus estimate is $-1.57 per share (range $-1.57 – $-1.57) across 1 analysts. Full-year EPS is projected at —, rising to $-5.28 the following year.
How much revenue is Artelo Biosciences Inc expected to report next quarter?+
Consensus revenue is — (range — – —). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading ARTL lately?+
As of Nov 19, 2026, 0 of 1 active firms rate ARTL a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ARTL calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.